# Phase 2a Study of BAX69 and 5-FU/Leucovorin or Panitumumab Versus Standard of Care in Subjects With Metastatic Colorectal Cancer

> **NCT02448810** · PHASE2 · TERMINATED · sponsor: **Baxalta now part of Shire** · enrollment: 115 (actual)

## Conditions studied

- Metastatic Colorectal Cancer

## Interventions

- **BIOLOGICAL:** BAX69 + infusional 5-FU/LV
- **BIOLOGICAL:** BAX69 + panitumumab
- **BIOLOGICAL:** BAX69 + 5-FU/LV
- **BIOLOGICAL:** BAX69 + panitumumab
- **DRUG:** Standard of Care
- **BIOLOGICAL:** Standard of Care

## Key facts

- **NCT ID:** NCT02448810
- **Lead sponsor:** Baxalta now part of Shire
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-06-15
- **Primary completion:** 2017-02-15
- **Final completion:** 2017-02-15
- **Target enrollment:** 115 (ACTUAL)
- **Why stopped:** Based on overall benefit-risk assessment.
- **Last updated:** 2021-05-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02448810

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02448810, "Phase 2a Study of BAX69 and 5-FU/Leucovorin or Panitumumab Versus Standard of Care in Subjects With Metastatic Colorectal Cancer". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02448810. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*